These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20193792)

  • 1. Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Apr; 28(18):3143-51. PubMed ID: 20193792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV).
    Fine DL; Jenkins E; Martin SS; Glass P; Parker MD; Grimm B
    J Virol Methods; 2010 Feb; 163(2):424-32. PubMed ID: 19903494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.
    Martin SS; Bakken RR; Lind CM; Garcia P; Jenkins E; Glass PJ; Parker MD; Hart MK; Fine DL
    Vaccine; 2010 Jan; 28(4):1031-40. PubMed ID: 19914193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses.
    Fine DL; Roberts BA; Teehee ML; Terpening SJ; Kelly CL; Raetz JL; Baker DC; Powers AM; Bowen RA
    Vaccine; 2007 Feb; 25(10):1868-76. PubMed ID: 17240002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.
    Gupta P; Sharma A; Spurgers KB; Bakken RR; Eccleston LT; Cohen JW; Honnold SP; Glass PJ; Maheshwari RK
    Vaccine; 2016 May; 34(25):2762-5. PubMed ID: 27129427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genetic adjuvant IL-12 enhances the protective efficacy of a DNA vaccine for Venezuelan equine encephalitis virus delivered by intramuscular injection in mice.
    Suschak JJ; Bagley K; Six C; Shoemaker CJ; Kwilas S; Spik KW; Dupuy LC; Schmaljohn CS
    Antiviral Res; 2018 Nov; 159():113-121. PubMed ID: 30268913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates.
    Dupuy LC; Richards MJ; Ellefsen B; Chau L; Luxembourg A; Hannaman D; Livingston BD; Schmaljohn CS
    Clin Vaccine Immunol; 2011 May; 18(5):707-16. PubMed ID: 21450977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development.
    Sharma A; Gupta P; Glass PJ; Parker MD; Maheshwari RK
    Vaccine; 2011 Jan; 29(5):953-9. PubMed ID: 21115048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome.
    Tretyakova I; Tibbens A; Jokinen JD; Johnson DM; Lukashevich IS; Pushko P
    Vaccine; 2019 May; 37(25):3317-3325. PubMed ID: 31072736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of hamsters by Venezuelan equine encephalitis virus candidate vaccine V3526 against lethal challenge by mosquito bite and intraperitoneal injection.
    Turell MJ; Parker MD
    Am J Trop Med Hyg; 2008 Feb; 78(2):328-32. PubMed ID: 18256440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge.
    Henning L; Endt K; Steigerwald R; Anderson M; Volkmann A
    Front Immunol; 2020; 11():598847. PubMed ID: 33542715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product.
    Perkins SD; Williams AJ; O'Brien LM; Laws TR; Phillpotts RJ
    Viral Immunol; 2008 Dec; 21(4):451-7. PubMed ID: 19115934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge.
    Tretyakova I; Plante KS; Rossi SL; Lawrence WS; Peel JE; Gudjohnsen S; Wang E; Mirchandani D; Tibbens A; Lamichhane TN; Lukashevich IS; Comer JE; Weaver SC; Pushko P
    Vaccine; 2020 Apr; 38(17):3378-3386. PubMed ID: 32085953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates.
    Fine DL; Roberts BA; Terpening SJ; Mott J; Vasconcelos D; House RV
    Vaccine; 2008 Jun; 26(27-28):3497-506. PubMed ID: 18508163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates.
    Dupuy LC; Richards MJ; Reed DS; Schmaljohn CS
    Vaccine; 2010 Oct; 28(46):7345-50. PubMed ID: 20851089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Engineered Mesenchymal Cells Improve Passive Immune Protection Against Lethal Venezuelan Equine Encephalitis Virus Exposure.
    Braid LR; Hu WG; Davies JE; Nagata LP
    Stem Cells Transl Med; 2016 Aug; 5(8):1026-35. PubMed ID: 27334491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation.
    Hannaman D; Dupuy LC; Ellefsen B; Schmaljohn CS
    Vaccine; 2016 Jun; 34(31):3607-12. PubMed ID: 27206386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice.
    Hart MK; Pratt W; Panelo F; Tammariello R; Dertzbaugh M
    Vaccine; 1997 Mar; 15(4):363-9. PubMed ID: 9141206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters.
    Jahrling PB; Stephenson EH
    J Clin Microbiol; 1984 Mar; 19(3):429-31. PubMed ID: 6715512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus.
    Reed DS; Lind CM; Lackemeyer MG; Sullivan LJ; Pratt WD; Parker MD
    Vaccine; 2005 May; 23(24):3139-47. PubMed ID: 15837213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.